← All Sponsors
SPONSOR

Ferring Pharmaceuticals

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374 Phase 3
Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Intermediate Risk Non-Muscle Invasive Bladder Cancer
United States, Canada, France View Trial →